Clinical Trial Update: Study of CD19 CAR-T Therapy for Refractory SLE [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating a CD19 CAR-T cell therapy for refractory systemic lupus erythematosus, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• CD19 CAR-T therapy (CD19-targeted CAR-T cell therapy)

Snippet

Sponsor: Chongqing Precision Biotech Co., Ltd | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: RECRUITING